Serum lncRNA LINC01535 as Biomarker of Diagnosis, Prognosis, and Disease Progression in Breast Cancer
Clinical Breast Cancer · 2023
DOI: 10.1016/j.clbc.2023.05.004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Breast Cancer, 2023. Verfasst von Yi Peng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery, Fujian Provincial Maternity and Children's Hospital, Fuzhou, China. Electronic address: pengyi831010@163.com. Hauptthemen laut MEDLINE: MicroRNAs, RNA, Long Noncoding, Breast Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Breast cancer has become the world's leading cancer, the leading killer of women's health, with a high mortality rate. With the development of medical technology, lncRNAs are widely used in the diagnosis and prognosis of various tumors, so finding new specific molecular markers and targets is the key to prolonging the survival time of breast cancer patients. MATERIALS AND METHODS: The expressions of lncRNA LINC01535 and miR-214-3p in breast cancer were detected by quantitative real-time PCR (qRT-PCR). The diagnostic significance of LINC01535 in breast cancer was assessed by ROC curve. The prognostic value of LINC01535 was verified by Kaplan-Meier method. The regulation of low expression of LINC01535 on proliferation and other biological abilities of breast cancer cells was determined by CCK-8 and Transwell method. The luciferase activity report assays indicated the relationship between LINC01535 and miR-214-3p. RESULTS: LINC01535 was elevated in breast cancer, which was negatively correlated with miR-214-3p, and miR-214-3p expression was decreased. LINC01535 proved to be promising in the diagnosis and prognosis of breast cancer. Low expression of LINC01535 targeting miR-214-3p had regulatory significance on tumor progression, lymph node metastasis and TNM stage. CONCLUSION: Silencing LINC01535 inhibited the proliferation capacity, migration level and invasion of breast cancer cells in vitro. LINC01535 was likely to be the focus of continued attention as a diagnostic and prognosis marker for breast cancer in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Surgery, Fujian Provincial Maternity and Children's Hospital, Fuzhou, China. Electronic address: pengyi831010@163.com.
- Department of Breast Surgery, Fujian Provincial Maternity and Children's Hospital, Fuzhou, China.
Zitieren
APA
Peng, Y., Huang, X., & Wang, H. (2023). Serum lncRNA LINC01535 as Biomarker of Diagnosis, Prognosis, and Disease Progression in Breast Cancer. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2023.05.004
Vancouver
Peng Y, Huang X, Wang H. Serum lncRNA LINC01535 as Biomarker of Diagnosis, Prognosis, and Disease Progression in Breast Cancer. Clinical Breast Cancer. 2023. doi:10.1016/j.clbc.2023.05.004
BibTeX
@article{Peng2023,
author = {Peng, Yi and Huang, Xiaoxi and Wang, Hongmei},
title = {Serum lncRNA LINC01535 as Biomarker of Diagnosis, Prognosis, and Disease Progression in Breast Cancer},
journal = {Clinical Breast Cancer},
year = {2023},
doi = {10.1016/j.clbc.2023.05.004}
}
EUVIMED